2021
Update on gout management: what is old and what is new
Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Current Opinion In Rheumatology 2021, 34: 118-124. PMID: 34907116, PMCID: PMC8799507, DOI: 10.1097/bor.0000000000000861.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyRisk factorsAdjunctive management strategiesUrate-lowering efficacyChronic kidney diseaseUse of allopurinolAllopurinol hypersensitivity syndromeManagement of hyperuricemiaCrystal-Associated Disease NetworkPopulation attributable riskEvidence-based recommendationsComprehensive evidence-based recommendationsNew drug therapiesGout guidelinesCause mortalityHypersensitivity syndromeCardiovascular riskGout flaresGout managementKidney diseaseDrug therapyFlare managementAttributable riskDietary factorsSerum urateRole of diet in hyperuricemia and gout
Danve A, Sehra ST, Neogi T. Role of diet in hyperuricemia and gout. Best Practice & Research Clinical Rheumatology 2021, 35: 101723. PMID: 34802900, PMCID: PMC8678356, DOI: 10.1016/j.berh.2021.101723.Peer-Reviewed Original ResearchConceptsDietary factorsLong-term clinical courseWeight lossMainstay of therapyUrate-lowering therapySerum urate levelsRole of dietLow purine dietTreatment of goutGout outcomesInflammatory arthritisClinical courseDefinitive managementDietary ApproachesGout flaresUrate levelsGlobal burdenGoutHyperuricemiaIndividual foodsHigh fructose corn syrupCertain foodsLimited evidenceVitamin CCommon form
2020
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & Rheumatology 2020, 72: 879-895. PMID: 32390306, DOI: 10.1002/art.41247.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyManagement of goutGout flaresFirst-line urate-lowering therapyInitiation of ULTSevere chronic kidney diseaseFrequent gout flaresLower starting doseSerum urate measurementsChronic kidney diseaseNonsteroidal antiinflammatory drugsTarget management strategyConsensus processRheumatology guidelinesSU targetDose titrationRecommendations AssessmentStarting doseProphylaxis therapyRadiographic damageGRADE methodologyTophaceous goutKidney diseasePatient preferencesAntiinflammatory drugs2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research 2020, 72: 744-760. PMID: 32391934, PMCID: PMC10563586, DOI: 10.1002/acr.24180.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyManagement of goutGout flaresFirst-line urate-lowering therapyInitiation of ULTSevere chronic kidney diseaseFrequent gout flaresLower starting doseSerum urate measurementsChronic kidney diseaseNonsteroidal antiinflammatory drugsTarget management strategyConsensus processRheumatology guidelinesSU targetDose titrationRecommendations AssessmentStarting doseProphylaxis therapyRadiographic damageGRADE methodologyTophaceous goutKidney diseasePatient preferencesAntiinflammatory drugs